Grafalon® vs. Thymoglobulin® as an induction agent in renal transplantation – A retrospective study
| Autor: | Dinesh Bansal, Amit Mahapatra, Pranaw Kumar Jha, Dinesh Kumar Yadav, Puneet Sodhi, Sidharth Kumar Sethi, Vijay Kher, Ashish Nandwani, Shyam Bihari Bansal, Manish Jain, Ashwini Gadde, Ajay Kher, Abhyudaysingh Rana |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
thymoglobulin
medicine.medical_specialty Thymoglobulin business.industry medicine.medical_treatment Urology india rabbit Renal function kidney transplantation Retrospective cohort study Immunosuppression medicine.disease Diseases of the genitourinary system. Urology Transplantation Nephrology Median follow-up Prednisolone medicine Original Article RC870-923 business antilymphocyte serum Kidney transplantation medicine.drug |
| Zdroj: | Indian Journal of Nephrology, Vol 31, Iss 4, Pp 336-340 (2021) Indian Journal of Nephrology |
| ISSN: | 1998-3662 0971-4065 |
| Popis: | Introduction: Antihuman thymocyte immunoglobulin, used as an induction agent in renal transplantation, is of two types – thymoglobulin and grafalon (formerly ATG-Fresenius). In this study, we compared outcomes with these two agents. Methods: This was a single-center retrospective study of patients transplanted from January 2017 to October 2019, who received either grafalon or thymoglobulin induction. Grafalon or thymoglobulin was given at 6 and 3 mg/kg, respectively, followed by standard triple immunosuppression of tacrolimus, MMF, and prednisolone. Results: Median follow up was 22 (3–36) months. Thymoglobulin was given to 255 patients, whereas 78 patients received grafalon. Baseline demographics were similar between the two groups although significantly more patients in the grafalon group received ABO incompatible transplant (15% vs. 4.3%; P = 0.002). Patient survival was similar between the two groups (99% in grafalon vs. 98.8% in thymoglobulin; P = 1.0). Death censored graft survival was also similar (99% in grafalon vs. 100% in thymoglobulin; P = 0.23). Biopsy proven acute rejection (BPAR) was significantly higher in the grafalon group (12.8% vs. 5.1%, P = 0.04). The significance persisted after multivariable regression analysis (P = 0.02). Other outcomes such as infection rate and estimated glomerular filtration rate on last follow up were comparable between the two groups. Conclusions: Grafalon (6 mg/kg dose) when used as an induction agent was associated with significantly higher rate of BPARs as compared to thymoglobulin (3 mg/kg dose) although with comparable short-term patient and death censored graft survival, graft function, and infection rates. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|